Humana Earnings Preview: What to Expect

Humana Earnings Preview: What to Expect

Humana Inc. (HUM), headquartered in Louisville, Kentucky, provides medical and specialty insurance products. With a market cap of $47.2 billion, the company offers coordinated health care through health maintenance organizations, point-of-service plans, and administrative services products. The medicare giant is expected to announce its fiscal second-quarter earnings for 2026 before the market opens on Wednesday, Jul. 29.

Ahead of the event, analysts expect HUM to report a profit of $6.17 per share on a diluted basis, down 1.6% from $6.27 per share in the year-ago quarter. The company beat the consensus estimates in three of the last four quarters while missing the forecast on another occasion.

More Top Stocks Daily: Go behind Wall Street’s hottest headlines with Barchart’s Active Investor newsletter.

 

For the full year, analysts expect HUM to report EPS of $9.03, down 47.3% from $17.14 in fiscal 2025. However, its EPS is expected to rise 65.8% year over year to $14.97 in fiscal 2027. 

www.barchart.com

HUM stock has outperformed the S&P 500 Index’s ($SPX) 20% gains over the past 52 weeks, with shares up 63.9% during this period. Similarly, it outperformed the State Street Health Care Select Sector SPDR ETF’s (XLV19.5% returns over the same time frame.

www.barchart.com

On Apr. 29, HUM shares closed up by 5.8% after reporting its Q1 results. Its adjusted EPS of $10.31 surpassed Wall Street expectations of $9.97. The company’s revenue was $39.7 billion, beating Wall Street forecasts of $39.5 billion.

Analysts’ consensus opinion on HUM stock is reasonably bullish, with a “Moderate Buy” rating overall. Out of 27 analysts covering the stock, eight advise a “Strong Buy” rating, one suggests a “Moderate Buy,” 16 give a “Hold,” and two recommend a “Strong Sell.” While HUM currently trades above its mean price target of $307.83, the Street-high price target of $441 suggests an upside potential of 12.3%.


On the date of publication, Neha Panjwani did not have (either directly or indirectly) positions in any of the securities mentioned in this article. All information and data in this article is solely for informational purposes. For more information please view the Barchart Disclosure Policy here.

 

More news from Barchart

Berkshire Hathaway Stock Rallied Last Month But Don’t Expect Fireworks in H2 Dow Jones Stocks Could Be the Perfect Portfolio for 2026 Now That Google’s in the Mix. Here’s 3 Ways to Profit. Wall Street’s AI Spending Warning Could Make Nvidia the Biggest Casualty Rocket Lab Just Changed Its Growth Story With One Bold $8B Deal